Baseline characteristics of overall population (n=365) and according to chemotherapy response score (CRS)
| Overall (n=365) | CRS 1–2 (n=277) | CRS 3 (n=88) | P value | |
| Age (years), n (%) | 0.770 | |||
| ≤60 | 161 (44.1) | 121 (43.7) | 40 (45.5) | |
| >60 | 204 (55.9) | 156 (56.3) | 48 (54.5) | |
| Median (range) | 62 (21–88) | 63 (21–88) | 62 (38–83) | 0.953 |
| BMI (kg/m2), median (range) Missing | 24.1 (15.6–52.0) 13 (-) | 24.1 (15.6–52.0) 8 (-) | 24.3 (16.4–44.6) 5 (-) | 0.795 |
| WHO performance status, n (%) | 0.163 | |||
| 0 | 211 (59.4) | 159 (59.3) | 52 (59.8) | |
| 1 | 125 (35.2) | 98 (36.6) | 27 (31.0) | |
| ≥2 | 19 (5.4) | 11 (4.1) | 8 (9.2) | |
| Missing | 10 (-) | 9 (-) | 1 (-) | |
| Preoperative CA125 (UI/mL), median (range) Missing | 885.0 (5–86000) 27 (-) | 868.5 (11–42110) 21 (-) | 896.5 (5–86000) 6 (-) | 0.750 |
| FIGO stage, n (%) | 0.314 | |||
| IIIC | 282 (77.3) | 219 (79.1) | 63 (71.6) | |
| IV | 83 (22.7) | 58 (20.9) | 25 (28.4) | |
| Histological subtype, n (%) | 0.578 | |||
| Serous carcinoma | 341 (94.2) | 258 (93.8) | 83 (95.4) | |
| High-grade | 275 (93.9) | 211 (92.5) | 64 (98.5) | |
| Low-grade | 18 (6.1) | 17 (7.5) | 1 (1.5) | |
| Grade N/A | 48 (-) | 30 (-) | 18 (-) | |
| Endometrioid carcinoma | 10 (2.8) | 7 (2.5) | 3 (3.4) | |
| Carcinosarcoma | 6 (1.7) | 6 (2.2) | 0 (0.0) | |
| Clear cell carcinoma | 2 (0.6) | 2 (0.7) | 0 (0.0) | |
| Mucinous carcinoma | 1 (0.3) | 1 (0.4) | 0 (0.0) | |
| Others | 2 (0.6) | 1 (0.4) | 1 (1.1) | |
| Missing | 3 (-) | 2 (-) | 1 (-) | |
| Ascites (liter), median (range) Missing | 1 (0–10) 51 (-) | 1 (0–10) 36 (-) | 1 (0–7.5) 15 (-) | 0.045 |
BMI, body mass index; CA125, cancer antigen 125; CRS, chemotherapy response score; FIGO, International Federation of Gynecology and Obstetrics; N/A, not available; WHO, World Health Organization.